Merck & Co. Inc. announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The agreement represents a key step toward public reimbursement of WINREVAIR® for use in combination with standard therapy for adults with World Health Organization Group 1 pulmonary arterial hypertension (PAH) and Functional Class II or III. The next phase involves implementation of reimbursement by provincial, territorial, and federal drug programs, based on established patient eligibility criteria.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via CNW (Ref. ID: C0427) on November 20, 2025, and is solely responsible for the information contained therein.